On October 23, 2013, the China Food and Drug Administration (CFDA) released a Guiding Opinion entitled “Increasing the Capacity of Provinces to Conduct Medical Device Evaluations (Guiding Opinion).”
It is not uncommon for one of our China lawyers to receive an email along the following lines.
Since the Anti-monopoly Law of the People’s Republic of China (“AML”) came into effect, there has been much debate about the circumstances in which minimum resale price maintenance (“RPM”) will constitute a vertical monopolistic agreement prohibited by Article 14 of the AML.
On October 222013 the Supreme People’s Court held a press conference in Beijing to present eight leading IP court decisions in civil and criminal cases. Trademark owners might find that these cases help resolve some long-lasting concerns, including a lack of deterrence against infringement, the insufficient amounts of damages awarded, and the difficulties in obtaining interim injunctive relief.
On October 25, 2013, the Standing Committee of National People’s Congress (“SCNPC”) passed the amendment (“Amendment”) to the Law on Protection of Consumers’ Rights and Interests (“CPL”), which will enter into force on the 15th of March 2014. This Amendment is significant to both consumers and business operators as it is the first time in twenty years that China makes substantial amendments to the CPL.